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In the search for new therapeutic tools against tuberculosis two novel iron complexes, [Fe(L–H)3], with 3-
aminoquinoxaline-2-carbonitrile N1,N4-dioxide derivatives (L) as ligands, were synthesized, characterized by
a combination of techniques, and in vitro evaluated. Results were compared with those previously reported
for two analogous iron complexes of other ligands of the same family of quinoxaline derivatives. In addition,
the complexes were studied by cyclic voltammetry and EPR spectroscopy. Cyclic voltammograms of the iron
compounds showed several cathodic processes which were attributed to the reduction of the metal center
(Fe(III)/Fe(II)) and the coordinated ligand. EPR signals were characteristic of magnetically isolated high-spin
Fe(III) in a rhombic environment and arise from transitions between mS=±1/2 (geff~9) or mS=±3/2
(geff~4.3) states. Mössbauer experiments showed hyperﬁne parameters that are typical of high-spin Fe(III)
ions in a not too distorted environment. The novel complexes showed in vitro growth inhibitory activity on
Mycobacterium tuberculosis H37Rv (ATCC 27294), together with very low unspeciﬁc cytotoxicity on
eukaryotic cells (cultured murine cell line J774). Both complexes showed higher inhibitory effects on M.
tuberculosis than the “second-line” therapeutic drugs.
© 2010 Elsevier Inc. All rights reserved.
1. Introduction
According to WHO (World Health Organization), infectious and
parasitic diseases are major causes of human disease worldwide. In
particular, tuberculosis (TB), an ancient and currently re-emerging
infectious disease, still remains a public health issue at the beginning
of the 21st century [1]. This airborne and highly contagious bacterial
disease is transmitted from person to person via droplets from the
throat and lungs of people with the active respiratory disease. It is
produced by mycobacteria, mainly Mycobacterium tuberculosis. In
healthy people, infection often causes no symptoms, since the
person's immune system acts to wall off the bacteria. Currently, a
rising number of people contract TB (often accompanied by other
bacterial infections) because their immune systems are compromised
by immunosuppressive drugs, abuse substances, or HIV/AIDS, among
others. Besides, the increasing emergence of multi-drug-resistant
strains has also contributed to the alarming high morbidity and
mortality of this endemia [2]. As a result, TB is one of the current
leading causes of death in the world. The WHO estimates that about
30 million people will be infected in the next 20 years, not only in the
developing countries but also in the developed world. Due to these
facts TB currently receives a higher level of attention from health
systems than other communicable diseases.
In view of the importance of this disease and the increasing
incidence of drug-resistant strains, the investigation and development
of new drugs is a leading area of research.
Two main approaches are currently being investigated for
developing new anti-TB drugs [3]. One of them is based on the
synthesis of analogues of existing drugs with the aim of shortening
and improving TB treatment. The other one involves the search for
novel structures that the mycobacteria have never been presented
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with before. In the context of this second approach, our research is
focused on the synthesis and characterization of new iron–quinoxa-
line derivative compounds with the aim of obtaining new and more
potent anti-TB compounds which can improve the current chemo-
therapeutic treatments.
The study of quinoxaline derivatives has become of much interest
in recent years because of their antibacterial, antiviral, anticancer,
antifungal, antihelminthes and insecticidal activities [4]. Part of our
group has been involved in the synthesis and biological assessment of
a large amount of quinoxaline 1,4-di-N-oxide derivatives, including
some of their metal complexes [5–10]. Some of these organic
derivatives have shown excellent M. tuberculosis growth inhibition
values. It has been observed that generally the lack of the two N-oxide
groups has lead to the loss of the antimycobacterial activity [11–14].
On the other hand, the relationship between iron, mycobacteria and
tuberculosis is well known. Treatment of several mycobacteria with p-
aminosalicylic acid (PAS), one of the oldest antituberculosis drugs,
resultedmore effectivewhen the cells were grownwith adequate iron
levels [15]. Besides, many iron complexes with different organic
molecules showed antimycobacterial activity. For instance, [Fe(CN)5
(isoniazide)]3− appears to be a promising molecule for further drug
development [16].
Taking into account these antecedents anddue to the fact thatduring
the last years we have been studying the effect ofmetal coordination on
the bioactivity of selected 3-aminoquinoxaline-2-carbonitrile N1,N4-
dioxide derivatives [5–10], we have recently developed two iron
complexes, [FeIII(L–H)3], with the derivatives L1 and L2 as ligands
(Fig. 1) and have evaluated their antimycobacterial activity [17]. Having
observed activity we decided to extend the work to other ligands of the
same family. In this work we report the synthesis, characterization and
in vitro evaluation of two further [FeIII(L–H)3] complexes with L=L3
and L4 (Fig. 1). Both new complexes were characterized by elemental
and conductimetric analyses and infrared (FTIR) and electronic spectro-
scopies. In addition, the compoundswere studied by cyclic voltammetry
and EPR spectroscopy. Mössbauer experimentswere performed to get a
deeper insight into the structure of the complexes. Their antimycobac-
terial activity was evaluated in vitro on M. tuberculosis H37Rv (ATCC
27294) and compared with that of the reference drug Isoniazid. In
addition, cytotoxicity on eukaryotic cells was evaluated on cultured
murine cell line J774.
2. Experimental
2.1. Materials
All common laboratory chemicals were purchased from com-
mercial sources and used without further puriﬁcation. The ligands
L1–L4 were synthesized by reaction of the corresponding benzofur-
oxan and malonitrile and characterized as previously described [18].
L2 and L4 were obtained as mixtures of 6- and 7-substituted isomers
[18].
High purity dimethyl sulfoxide (DMSO) (Aldrich) was used for the
electrochemical measurements. Tetrabutylammonium hexaﬂuoro-
phosphate (TBA)PF6, from Fluka (electrochemical grade) was
employed as supporting electrolyte. Extra-pure nitrogen was used
to remove oxygen from the DMSO solutions.
2.2. Syntheses of the complexes [Fe(L–H)3]
The complexes were synthesized by the following procedure:
0.12 mmol of L (25 mg L1, 28 mg L2, 32 mg L3, 32 mg L4) and
0.06 mmol (26 mg) of Fe(NO3)3 were mixed in methanol and reacted
under reﬂux during 6 h. Purple solids were ﬁltered off, washed with
methanol and dried at room temperature.
[Fe(L1–H)3]; (code Fe–L1) yield: 74%. Anal. calc. for
C27N12H15O6Fe: C, 49.19; H, 2.29; N, 25.49. Found: C, 49.21; H,
2.77; N, 25.59. ΛM(DMSO): 1 μS/cm2.
[Fe(L2–H)3]·5H2O; (code Fe–L2) yield: 59%. Anal. calc. for
C30N12H31O11Fe: C, 45.53; H, 3.00; N, 21.24. Found: C, 44.83; H,
2.57; N, 21.20. ΛM(DMSO): 2 μS/cm2. [Fe(L3–H)3]·H2O; (code Fe–
L3) yield: 45%. Anal. calc. for C30N12H20O10Cl3Fe: C, 41.33; H, 3.22;
N, 16.18. Found: C, 41.35; H, 3.28; N, 16.28. ΛM(DMSO): 8 μS/cm2.
[Fe(L4–H)3]·H2O; (code Fe–L4) yield: 80%. Anal. calc. for C30N12-
H14O7F9Fe: C, 40.87; H, 1.60; N, 19.07. Found: C, 41.72; H, 1.39; N,
19.47. ΛM(DMSO): 7 μS/cm2.
Even though the C analysis results for Fe-L2 and Fe-L4 are not quite
satisfactory, additional physicochemical characterizations of these
compounds (see below) are consistent with their formulae.
Fig. 1. Scheme showing the structure of the selected ligands (L) and the proposed structure for the iron(III) complexes [Fe(L–H)3]. Selected ligands: L: L1=3-aminoquinoxaline-2-
carbonitrile N1,N4-dioxide, L2=3-amino-6(7)-methylquinoxaline-2-carbonitrile N1,N4-dioxide, L3=3-amino-6(7)-chloro-7(6)-methoxyquinoxaline-2-carbonitrile N1,N4-dioxide
and L4=3-amino-6(7)-triﬂuoromethylquinoxaline-2-carbonitrile N1,N4-dioxide.
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2.3. Physicochemical characterization
C, H and N analyses were performed with a Carlo Erba Model
EA1108 elemental analyzer. Conductimetric measurements were
carried out at 25 °C in 10−3 M DMSO solutions using a Conductivity
Meter 4310 Jenway [19]. Conductivity was measured during 24 h to
assure the stability of the complexes in the solvent used for the
microbiological studies. Electronic spectra of the complexes were
registered on a Shimadzu UV-1603 spectrophotometer in DMSO
solution. FTIR spectra (4000–400 cm−1) of the complexes and the free
ligands were measured as KBr pellets with a Bomen FTIRmodel MB102
instrument. Cyclic voltammogramswere obtainedwith a PAR potentio-
stat/galvanostat model 263A controlled by the 270/250 Sofware (EG&G
Princeton Applied Research). A printer and a standard electrochemical
three electrode cell completed the system. Glassy carbon disc was
employed as working electrode. A platinum wire was used as counter
electrode, while an Ag/(10−3 M) AgNO3 in CH3CN/10−1 M (TBA)PF6,
was used as a reference electrode. This electrode was calibrated against
the [Fe(C5H5)2]/[Fe(C5H5)2]+ redox couple, for which a potential of
+0.4 V vs normal hydrogen electrode (NHE) was assumed [20,21]. All
potentials reported were referred to NHE in volts. Measurements were
performed in oxygen purged 10−3 M DMSO solutions of the complexes
containing 0.1 M (TBA)PF6 as supporting electrolyte. A continuous gas
streamwas passed over the solution during themeasurements. X-band
(9.5 GHz) EPR spectra were measured on a Bruker ELEXSYS E580
system (Bruker BioSpin, Germany) at 10 K. The temperature was
controlled with an Oxford ITC503 cryogenic system. Polycrystalline
samples of the title compounds were drawn in a quartz EPR tube and
then placed in the spectrometer rectangular cavity. All EPR data were
corrected by subtracting a baseline corresponding to the EPR signal of
the empty resonant cavity. Other acquisition conditions were:
modulation amplitude, 1 mT; modulation frequency, 100 kHz; micro-
wave power, 4 mW. The room temperature Mössbauer spectra were
taken in transmission geometry using a conventional constant
acceleration spectrometer of 512 channels with a 50 mCi nominal
activity 57Co source in a Rh matrix. The hyperﬁne parameters were
obtained by ﬁtting the data to lines of Lorentzian shape using a least-
squares computer code with constraints. Isomer shifts are calibrated
against an α-Fe foil at room temperature. According to the criterion of
Long et al. [22], to obtain the optimum signal to noise ratio, the absorber
thickness needed should be at least of 14 mg/cm2 of Fe, which
corresponds to an amount of compound of 137 mg/cm2. Because the
total amount of available compound was of only 104 mg, a special
absorber holder was assembled which contained the whole available
powder exposed to the gamma-ray beam in a cylinder of 8 mm
diameter with a collimator that prevented any other ray to reach the
detector.
2.4. Anti-M. tuberculosis activity assay
The anti-M. tuberculosis activity of the ligands and the iron
complexes was determined by the Resazurin Microtiter Assay
(REMA) [23]. Stock solutions of the test compounds were prepared
in DMSO anddiluted inMiddlebrook 7H9 broth (Difco), supplemented
with oleic acid, albumin, dextrose and catalase (OADC enrichment —
BBL/Becton Dickinson, Sparks, MD, USA), to obtain ﬁnal drug
concentration ranges from 0.15 to 250 μg/mL. The serial dilutions
were realized in Precision XS Microplate Sample Processor (Biotek™).
The isoniazid was dissolved in distilled water, according to the
manufacturers' recommendations (Difco laboratories, Detroit, MI,
USA), and used as a standard drug. M. tuberculosis H37Rv ATCC
27294 was grown for 7 to 10 days in Middlebrook 7H9 broth
supplemented with OADC, plus 0.05% Tween 80 to avoid clumps.
Suspensions were prepared and their turbidities matched to the
optical density of theMcFarland no. 1 standard. After a further dilution
of 1:25 inMiddlebrook 7H9 broth supplementedwith OADC, 100 μL of
the culture were transferred to each well of a 96-well microtiter plate
(NUNC), together with the test compounds. Each test was set up in
triplicate. Microplates were incubated for 7 days at 37 °C, after which
resazurin was added for the reading. Wells that turned from blue to
pink, with the development of ﬂuorescence, indicated growth of
bacterial cells while maintenance of the blue color indicated bacterial
inhibition [23,24]. The ﬂuorescence was read (530 nm excitation ﬁlter
and 590 nm emission ﬁlter) in a SPECTRAﬂuor Plus (Tecan) micro-
ﬂuorimeter. TheMICwas deﬁned as the lowest concentration resulting
in 90% inhibition of growth of M. tuberculosis [23]. As a standard test,
the MIC of isoniazid was determined on each microplate. The
acceptable range of isoniazid MIC is from 0.015 to 0.05 μg/mL [23,24].
2.5. Citotoxicity assay
In vitro cytotoxicity assays (IC50) were performed on the J774A.1
(ATCC TIB-67) cell line, as recommended by Ahmed et al. [25] and
modiﬁed by us [26]. The cells were routinely maintained in Complete
Medium (RPMI-1640 supplemented with 10% heat-inactivated fetal
bovine serum (FBS); 100 U/mL penicillin and 100 μg/mL streptomycin),
at 37 °C, in a humidiﬁed 5% CO2 atmosphere. After reaching conﬂuence,
the cells were detached and counted. For the cytotoxicity assay,
1×105 cells/mL were seeded in 200 μL of Complete Medium in 96-
well plates (NUNC). The plates were incubated at 37 °C under a 5% CO2
atmosphere for 24 h, to allow cell adhesion prior to drug testing. The
compounds were dissolved in DMSO and subjected to two-fold serial
dilution from 1250 to 3.9 μg/mL. Cells were exposed to the compounds
at various concentrations for a 24 h-period. Resazurin solutionwas then
added to the cell cultures and incubated for 6 h. Cell respiration was
followed asan indicator of cell viability andwasdetected by reductionof
resazurin to resoruﬁn, whose pink color and ﬂuorescence indicates cell
viability. A persistent blue color of resazurin is a sign of cell death
[23,24]. The ﬂuorescence measurements (530 nm excitation ﬁlter and
590 nmemission ﬁlter)were performed in a SPECTRAﬂuor Plus (Tecan)
microﬂuorimeter. The IC50 value was deﬁned as the highest drug
concentration at which 50% of the cells are viable relative to the control
[26]. A selectivity index (SI) was then calculated by dividing the IC50 by
the MIC.
3. Results and discussion
Two new iron(III) [Fe(L–H)3] complexes including the ligands L3
(3-amino-6(7)-chloro-7(6)-methoxyquinoxaline-2-carbonitrile N1,
N4-dioxide) and L4 (3-amino-6(7)-triﬂuoromethylquinoxaline-2-
carbonitrile N1,N4-dioxide) (Fig. 1) were synthesized with high
purities and yields. Unfortunately, it was impossible to obtain single
crystals adequate for a crystallographic study. Nevertheless, com-
plexes could be adequately characterized in the same way as
previously done for the reported copper, vanadium, palladium and
iron compounds of this family of ligands by using a combination of
several physicochemical methods [5–10]. Both complexes are neutral
non conducting compounds in DMSO. Analytical and conductimetric
results are in agreement with the proposed formula and structure
(Fig. 1). The conductivity was measured during 24 h and no major
changes were observed, demonstrating the stability of the complexes
in DMSO solution. Similar results were obtained by means of the
electrochemical measurements. The visible spectra of the ligands
showed two strong bands in the 508–510 nm and 363–368 nm
ranges. These bands obscured the predicted spin allowed d–d
transitions for the iron species. Therefore structural information
could not be obtained from these spectra.
3.1. Cyclic voltammetry
Cyclic voltammograms (CV) were run at incremental scan rates (v)
from 0.05 V/s to 2.0 V/s. Results for compounds L3 and Fe–L3were not
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included in the electrochemical study because they exhibited an
erratic voltammetric pattern; CV changes with time and no repro-
ducible curves were obtained. To exemplify the general electrochem-
ical behavior of the complexes the reduction of Fe–L1 and Fe–L2
complexes was studied at different scan rates (v) using glassy carbon
as working electrode in DMSO solutions and was compared with
those obtained for the free ligands.
L1 and L2 showed a similar behavior to that previously obtained in
this laboratory and discussed in detail with analogous compounds
using Pt as working electrode [10].
Comparison of the data reveals that no appreciable effects can be
ascribed to the electrode material. The voltammogram obtained for L1
at v=0.1 V/s, is shown in Fig. 2. Reduction peak potential values at
v=0.1 V/s are summarized in Table 1.
The ligands exhibit two reduction processes (labeled A and B) at
very close potentials, during the forward negative scan. As discussed
in detail elsewhere [10], the ﬁrst electron addition corresponds to the
reduction of the N1,N4 dioxide derivatives to a radical anion with
addition of a proton to the N–O group (see Scheme 1). After this step
cleavage of the N–OH bond occurs to give the mono-N-oxide
compound and the hydroxyl radical. The second electron addition is
consistent with the reduction and subsequent loss of the second oxide
group. These processes are followed by the quasi-reversible reduction
of the heterocycle itself (couple C/C´). The oxidation of a new
electroactive compound generated during the reduction cycle occurs
at potentials of peak D.
The cyclic voltammetric behavior of the complexes is similar to
that illustrated for the free ligands, but some differences are observed.
The complexes show a new peak (I) which corresponds to the
reduction of the metallic center from Fe(III) to Fe(II), on the forward
cathodic scan (Fig. 3 and Table 1). The species generated on this path
is stable on the time scale of the experiment, hence, giving rise to the
return peak (I′) in the voltammogram. The redox process (I/I′) is
quasi-reversible (ΔEpN60 mV) and the ratio of anodic to cathodic
peak currents (ipa/ipc) is near unity at all scan rates investigated (see
Fig. 3b) [27]. The current peak (I) of process increases with the square
root of the scan rate (ν1/2), approaching a single straight-line plot, in
accordance with diffusion control (see inset in Fig. 3b). Moreover, as
can be seen in Fig. 3a and b, the current peak of the second reduction
(AB) is approximately twice of the ﬁrst one. From this fact and from
reduction potential data we can infer that reduction processes labeled
A and B in the free ligands appear closely overlapped in the
voltamperometric response of the complexes (peak AB). Furthermore,
as ν increases the anodic counterpart of this peak is observed during
the reverse anodic scan in contrapositionwith the response of the free
ligand. The process appears to become more reversible when the
voltage scan is reversed before process C takes place and with
increasing scan rate (see inset of Fig. 3b). Thus, the coordination
modiﬁes the electrochemical behavior of the species formed during
these reduction paths.
In summary, results show that the reduction potential of both iron
compounds are similar and fall in the range previously reported for
other metal complexes of the same family of ligands. Despite this fact
and although a higher number of compounds would be needed for
establishing general conclusions, their behavioral analogy would
suggest that no apparent correlation exists between their redox
chemistry and their biological activity.
3.2. Spectroscopic measurements
3.2.1. IR spectra
The IR spectra of both new complexes were compared with those
of the free ligands and the previously reported Cu, V, Pd and Fe
complexes [5–10,17]. So, taking into account our previous knowledge
on vibrational behavior of 3-aminoquinoxaline-2-carbonitrile N1,N4-
dioxide derivatives metal complexes, vibration bands related with the
ligand's coordination mode were tentatively assigned. Selected
vibration bands and their assignments are depicted in Table 2.
All the complexes showed a similar spectroscopic behavior. Both
strong bands corresponding to νas(NH2) and νs(NH2) of the amino
group, located for the free ligands in the 3400 and 3250 cm−1 region,
disappeared after coordination and only one band (ν(NH)) of medium
intensity around 3300 cm−1 was observed. This is in accordance with
the presence of a secondary amine formed by deprotonation of the
primary amine as a consequence of the coordination with iron ion.
This behavior was previously observed for vanadyl, palladium and
copper complexes with this family of ligands, and for metal chelates
with aromatic ligands involving the amino group in ortho position to
the N-oxide [5–10,17,28]. Besides, the strong ν(N→O) band for the
free ligands turned weak upon complexation indicating the coordi-
nation of one N→O group per ligand molecule keeping the other
uncoordinated as shown in Fig. 1. In the case of Fe–L2 the
disappearance of the strong ν(N→O) band in the characteristic
range was probably due to the fact that the uncoordinated N→O
groups have additional interactions with other atoms from neighbor-
ing molecules, which form intermolecular bonds in the solid state.
This behavior was previously observed in related copper complexes
[9]. In addition changes in the ν(CN→O) bands were observed due to
complexation. The ν(C≡N) (2221–2246 cm−1) suffered only minor
changes upon complexation in agreement with the fact that this
group did not coordinate to iron ion. Taking into account the
stoichiometry found and the infrared spectral data, the proposed
structures for the complexes are shown in Fig. 1.
3.2.2. EPR spectra
The set of resonances observed in the experimental EPR spectra
(Fig. 4) can be interpreted on the basis of the spin Hamiltonian:
H=βg0.B.S+S.D.S, where β is the Bohr magneton, B is the applied
magnetic ﬁeld, and D is the zero-ﬁeld tensor used for SN1/2 systems.
The zero-ﬁeld term accounts for the deviations of the g-values from
2.0, thus giving rise to an effective g-value (geff), and its components
Fig. 2. Cyclic voltammograms at different potential limits of 1 mM L1 in DMSO solution.
Scan rate v=0.1 V/s.
Table 1
Electrode potentials (in V vs NHE) of selected complexes and the free ligands at
v=0.1 V/s.
Compound Epc(I)/Epa(I′) Epc(A) Ep(B) Epc(AB) Epc(C)
L1 – −0.92 −1.04 – −1.44
Fe–L1 −0.61/−0.53 – – −0.96 −1.42
L2 – −0.82 −0.97 – −1.48
Fe–L2 −0.62/−0.53 – – −0.98 −1.39
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(D and E) give information on the ligand coordination [29]. The low
temperature EPR spectra from polycrystalline samples of the Fe
compounds under study (Fe–L1, Fe–L2, Fe–L3, and Fe–L4) are all
characterized by a main intense resonance centered around 160 mT
that, when converted to g-value, gives an effective g of ca. 4.3. For Fe–
L1, Fe–L2, and Fe–L4, a weak resonance around 80 mT (geff~9) was
observed. These EPR signals are characteristic of magnetically isolated
high-spin Fe(III) in a rhombic environment [30,31] and arise from
transitions betweenmS=±1/2 (geff~9) ormS=3/2 (geff~4.3) states.
The somewhat broader linewidth of the geff~4.3 resonance can be
taken as a measure of the structural heterogeneity of the Fe centers
within the sample. The appearance of broad lines, especially in the
spectra of Fe–L1 and Fe–L3, is probably due to deviations of the local
symmetry around the Fe(III) ions from a fully rhombic (characterized
by a ratio E/D=1/3).
Scheme 1. Reduction steps of the N1,N4 dioxide derivatives.
Fig. 3. Cyclic voltammograms of 1 mM Fe–L1 in DMSO solution: a) at different cathodic limits, v=0.1 V/s; b) between +0.70 V and −1.20 V, at different scan rates. Inset of the
b: dependence of the cathodic current peak (I) on the square root of the scan rate.
Table 2
Tentative assignment of selected IR bands of the new iron complexes. Bands for the free
ligands and the previously reported Fe(III) complexes are included for comparison.
Compound νas(N–H) νs(N–H) νs(N–H) ν(CN) ν(N→O)
L1 3353 (s) 3262 (s) 2237 (w) 1343 (s)
Fe–L1 – – 3299 (s) 2221 (w) 1340 (vw)
L2 3331 (s) 3260 (m) 2232 (w) 1333 (s)
Fe–L2 – – 3314 (m) 2222 (w) –
L3 3365 (s) 3282 (m) 2238 (w) 1341 (s)
Fe–L3 – – 3327 (s) 2233 (w) 1340 (vw)
L4 3401 (s) 3282 (m) 2246 (w) 1348 (vs)
Fe–L4 – – 3366 (s) 2237 (w) 1343 (vw)
ν: stretching; νas: asymmetric stretching, νs: symmetric stretching, s: strong, m:medium,
w: weak, vw: very weak. Band positions are given in cm−1. Fig. 4. EPR spectra from polycrystalline samples of the Fe compounds measured at 10 K.
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3.2.3. Mössbauer spectra
The room temperature Mössbauer spectrum displays only one
central doublet (Fig. 5). The hyperﬁne parameters, shown in Table 3,
are typical of high-spin Fe(III) ions in a not too distorted environment.
There is a difference in the line intensities of the doublet. This
difference may be due to the trend of the sample to texture in the
absorber holder, i.e., the powder orients itself in a preferred orientation
with respect to the crystalline axes which made the L1/L2 ratio to be
different from the 1:1 expected ratio for a randomly oriented
polycrystalline sample. It might be due also to the well known
asymmetrywhich is a common feature of high-spin Fe(III) compounds
like FeCl3·6H2O [32,33].
3.3. Anti-M. tuberculosis activity
Both new complexes were evaluated in vitro for their antimyco-
baterial activities onM. tuberculosisH37Rv (ATCC 27294). Results were
compared to those of both previously reported iron(III) complexes
and the reference drug Isoniazid. The minimum inhibitory concen-
tration (MIC) values are depicted in Table 4.
All the ligands and the complexes were active against M.
tuberculosis. Iron complexes of L2, L3 and L4 resulted more active
than the corresponding free ligands, demonstrating that metal
coordination can favorably modify the proﬁle of antimycobacterial
activity of 3-aminoquinoxaline-2-carbonitrile N1,N4-dioxide deriva-
tives. Only the previously reported L1 complex showed less activity
than the free ligand. Both newly developed iron complexes showed
signiﬁcantly higher activity than the other complexes and the free
ligands. As previously reported for related copper, vanadyl and
palladium complexes [5–10], the change of the substituents on the
quinoxaline moiety produced signiﬁcant differences in biological
activity. The MIC values of L3 and L4 iron complexes (0.78 μg/mL) are
comparable or better than those of some “second-line” drugs in
clinical use as streptomycin (MIC=1.00 μg/mL), ciproﬂoxacin
(MIC=6 μM, 2.00 μg/mL), p-aminosalicylic acid (MIC=3.3–13.1 μM,
0.5–2.0 μg/mL), ethionamide (MIC=3.8–7.5 μM, 0.63–1.25 μg/mL),
cycloserine (MIC=122–490 μM, 12.5–50 μg/mL), gentamicin
(MIC=2.0–4.0 μg/mL), ethambutol (MIC=4.6–9.2 μM, 0.94–
1.88 μg/mL), kanamycin (MIC=1.25–5.0 μg/mL), tobramycin
(MIC=2.8–5.6 μM, 4.0–8.0 μg/mL), clarithromycin (MIC=10.7–
21.4, 8.0–16 μg/mL) and thiacetazone (MIC=0.53–8.5 μM, 0.125–
2.0 μg/mL) [24,34,35].
Iron is an essential nutrient for all living organisms. It is well
known that microorganisms and particularly M. tuberculosis have
evolved specialized iron transport systems to include iron inside the
cells. The developed iron complexes could act as carriers of the
bioactive ligands, producing a concentration increase of these
molecules inside the mycobacteria cells.
3.4. Unspeciﬁc cytotoxicity on murine J774 cells
Table 4 shows the IC50 values of the complexes and the ligands on
mammalian cells. All of them presented low citotoxicity, with high
selectivity indexes SI (selectivity index=IC50/MIC). Usually, com-
pounds showing SI values higher than 10 are considered suitable to be
further evaluated as potential anti-TB drugs. All the iron complexes
showed SI values higher than 20. SI values depicted in Table 4 show
that particularly Fe–L3 has a very low MIC value (high inhibitory
activity) and a very low cytotoxicity. It constitutes a promising new
potent chemotherapeutic alternative to be further evaluated in vivo in
experimental models of TB.
4. Conclusions
Two new Fe(III) complexes with selected 3-aminoquinoxaline-2-
carbonitrile N1,N4-dioxide derivatives as ligands, [Fe(L–H)3], have
been synthesized in satisfactory yields and characterized by different
techniques. The novel complexes showed in vitro bacteriostatic or
bactericide activity on the causative agent of TB M. tuberculosis,
showing very low unspeciﬁc cytotoxicities on eukaryotic cells. Both
showed higher inhibitory effects than the “second-line” therapeutic
drugs. Accordingly, these compounds could be useful as hospital
desinfectants, as therapeutical agents for instance for the treatment of
skin infections produced by mycobacteria together with antiseptics
and/or as drugs for the treatment of TB or other mycobacterioses.
Further work is in progress in order to get more biological details of
the action of these compounds on M. tuberculosis and to further
evaluate these promising compounds.
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Fig. 5. Room temperature Mössbauer spectrum of [Fe(L1–H)3]. The hollow circles are
the experimental points and the solid line is the result of the least-squares ﬁtting
described in the text using the parameters shown in Table 3.
Table 3
Hyperﬁne parameters yielded by the least square ﬁtting to lorentzian lines of the
spectrum.
Δ (mm/s) δ (mm/s)a L1/L2 Γ (mm/s)
0.65±0.03 0.40±0.01 1.14±0.02 0.46±0.01
a The isomer shift δ is referred to a foil of α-Fe at room temperature.
Table 4
MIC values (μg/mL, μg of L/mL and μM) of the Fe(III) complexes and the free ligands
against M. tuberculosis H37Rv (ATCC 27294).
Compound MIC (μg/mL)a MIC (μg of L/mL)b MIC (μM)c IC50 (μg/mL)d SIe
Fe–L1 7.8 7.1 11.8 156.3 20
Fe–L2 3.9 3.2 4.9 156.3 40
Fe–L3 0.78 0.67 0.89 312.5 400
Fe–L4 0.78 0.69 0.87 19.5 25
L1 5.0 5.0 24.7 156.3 31
L2 6.2 6.2 28.7 156.3 25
L3 3.9 3.9 14.5 312.5 80
L4 6.2 6.2 22.7 39.0 6
a MIC: minimum inhibitory concentration in μg/mL.
b MIC: minimum inhibitory concentration recalculated considering μg of ligand L
included per μg of complex Fe–L.
c MIC: minimum inhibitory concentration in μM.
d IC50: 50% inhibitory concentration on J774 murine cells.
e SI: selectivity index=IC50/MIC(μg/mL).
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